Zhang N, Gordon ML (2018)
Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients
Clin Interv Aging 13: 1963

Homma A, Atarashi H, Kubota N, Nakai K, Takase T (2016)
Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial
J Alzheimers Dis 52: 345

Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003)
beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies
Biochemical Pharmacology 65: 407

Alagiakrishnan K, Wong W, Blanchette PL (2000)
Use of donepezil in elderly patients with Alzheimer's disease--a Hawaii based study
Hawaii Med J 59: 57

Camps P, Cusack B, Mallender WD, Achab RE, Morral J, Munoz-Torrero D, Rosenberry TL (2000)
Huprine X is a Novel High-Affinity Inhibitor of Acetylcholinesterase That Is of Interest for Treatment of Alzheimer's Disease
Molecular Pharmacology 57: 409

Cummings JL, Donohue JA, Brooks RL (2000)
The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease
American Journal of Geriatry & Psychiatry 8: 134

Jann MW (2000)
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
Pharmacotherapy 20: 1

Kaur J, Zhang MQ (2000)
Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors
Curr Med Chem 7: 273

Kosasa T, Kuriya Y, Matsui K, Yamanishi Y (2000)
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats
European Journal of Pharmacology 389: 173

Ogura H, Kosasa T, Araki S, Yamanishi Y (2000)
[Pharmacological properties of donepezil hydrochloride (Aricept), a drug for Alzheimer's disease]
Nihon Yakurigaku Zasshi 115: 45

Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000)
Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats
Methods Find Exp Clin Pharmacol 22: 89

Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000)
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro
Methods Find Exp Clin Pharmacol 22: 609

Sugimoto H, Iimura Y, Kawakami Y, Yamanishi Y (2000)
Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors
Curr Med Chem 7: 303

Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA (2000)
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients
J Clin Psychiatry 61: 487

Doody RS (1999)
Clinical profile of donepezil in the treatment of Alzheimer's disease
Gerontology 45: 23

Kryger G, Silman I, Sussman JL (1999)
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs
Structure 7: 297

Lopez-Pousa S, Lombardia Fernandez C (1999)
[Treatment of Alzheimer's disease: acetylcholinesterase inhibitors].
Neurologia 14: 180

Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX, Feng B (1999)
Huperzine-A in capsules and tablets for treating patients with Alzheimer disease
Zhongguo Yao Li Xue Bao 20: 486

Barner EL, Gray SL (1998)
Donepezil use in Alzheimer disease
Annals of Pharmacotherapy 32: 70

Cheng DH, Tang XC (1998)
Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities
Pharmacol Biochem Behav 60: 377

Collier J (1998)
Drug and Therapeutics Bulletin defends its stance over donepezil [letter]
British Medical Journal 316: 1092

Costagli C, Galli A (1998)
Inhibition of cholinesterase-associated aryl acylamidase activity by anticholinesterase agents: focus on drugs potentially effective in Alzheimer's disease
Biochemical Pharmacology 55: 1733

Giacobini E (1998)
Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications
Neurochem Int 32: 413

Hasegawa K (1998)
How to cope with Alzheimer's disease?
Neurobiology of Aging 19: S107

Kryger G, Silman I, Sussman JL (1998)
Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica
Journal de Physiologie Paris 92: 191

Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998)
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group
Archives of Internal Medicine 158: 1021

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998)
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
Neurology 50: 136

Rogers SL, Friedhoff LT (1998)
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study
European Neuropsychopharmacology 8: 67

Ross JS, Shua-Haim JR (1998)
Aricept-induced nightmares in Alzheimer's disease: 2 case reports [letter]
J Am Geriatr Soc 46: 119

Svensson AL, Nordberg A (1998)
Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells
Neuroreport 9: 1519

Taverni JP, Seliger G, Lichtman SW (1998)
Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation
Brain Injury 12: 77

Wang T, Tang XC (1998)
Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine
European Journal of Pharmacology 349: 137

Anderson R, Higgins GA (1997)
Absence of central cholinergic deficits in ApoE knockout mice
Psychopharmacology (Berl) 132: 135

Boothby H, Zaidi SM, Seth V, Khalaf S, Jameel H, Mahomed S, al Y (1997)
Advertisements for donepezil. National policy needs to be set for prescribing of this drug
BMJ 315: 1624

Bryson HM, Benfield P (1997)
Drugs & Aging 10: 234

Geldmacher DS (1997)
Donepezil (Aricept) therapy for Alzheimer's disease
Compr Ther 23: 492

Gray S (1997)
Advertisements for donepezil (Aricept) in the BMJ. Advertisement suggests an unrealistic improvement in mental status
BMJ 314: 1555

Jones RW, Mann JB, Saunders SA (1997)
Advertisements for donepezil. Prices charged for private prescriptions for donepezil show huge variation
BMJ 315: 1624

Kojima J, Nakajima K, Ochiai M, Nakayama K (1997)
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia [published erratum appears in Methods Find Exp Clin Pharmacol 1997 Jun;19(5):364]
Methods Find Exp Clin Pharmacol 19: 245

McGuffey EC (1997)
Alzheimer's disease: an overview for the pharmacist
J Am Pharm Assoc 3: 347

Rupniak NM, Tye SJ, Field MJ (1997)
Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys
Psychopharmacology 131: 406

Tsukada H, Kakiuchi T, Ando I, Ouchi Y (1997)
Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: a positron emission tomography study in unanesthetized monkeys
Journal of Pharmacology & Experimental Therapeutics 281: 1408

Wagner N (1997)
Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil
BMJ 314: 1555

Whitehouse PJ, Juengst E, Mehlman M, Murray TH (1997)
Enhancing cognition in the intellectually intact
Hastings Center Report 27: 14

Wilkinson D (1997)
Advertisements for donepezil. Review of drug in Drug and Therapeutics Bulletin is uninformed
BMJ 315: 1625

Cheng DH, Ren H, Tang XC (1996)
Huperzine A, a novel promising acetylcholinesterase inhibitor
Neuroreport 8: 97

Inoue A, Kawai T, Wakita M, Iimura Y, Sugimoto H, Kawakami Y (1996)
The simulated binding of (+/-)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]m eth yl] -1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses
Journal of Medicinal Chemistry 39: 4460

Rogers SL, Friedhoff LT (1996)
The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo- Controlled Trial. The Donepezil Study Group
Dementia 7: 293

Matsui K, Oda Y, Ohe H, Tanaka S, Asakawa N (1995)
Direct determination of E2020 enantiomers in plasma by liquid chromatography-mass spectrometry and column-switching techniques
Journal of Chromatography A 694: 209

Nochi S, Asakawa N, Sato T (1995)
Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020)
Biol Pharm Bull 18: 1145

Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K (1995)
Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2- yl)methyl]piperidine hydrochloride and related compounds
Journal of Medicinal Chemistry 38: 4821

Galli A, Mori F, Benini L, Cacciarelli N (1994)
Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020
European Journal of Pharmacology 270: 189

Pang YP, Kozikowski AP (1994)
Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program
J Comput Aided Mol Des 8: 683

Dawson GR, Iversen SD (1993)
The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory
Behavioural Brain Research 57: 143